(lp0
S"Array Biopharma  Withdraws NDA for Binimetinib Monotherapy to Treat Melanoma StreetInsider.com - 20 hours ago Array BioPharma Inc.  today announced that it has withdrawn from the U.S. Food and Drug Administration's  Division of Oncology Products 2 its new drug application  for binimetinib monotherapy for the treatment of NRAS-mutant&nbsp;...Array Biopharma Inc: Withdraws marketing application - Times of IndiaCowen Sees Array Biopharma Inc  Share Weakness as Attractive Despite NDA ... - Smarter Analyst"
p1
aS"Array Biopharma's 12% Drop, Explained Benzinga - 16 hours ago Shares of Array Biopharma Inc , a biopharmaceutical company that focuses on drugs to treat patients suffering from cancer, lost more than 12 percent early Monday morning after announcing a disappointing update to one of its therapies.Array BioPharma Inc.  withdrawn from US Food and drug ... - Benchmark MonitorShort interest Of Array BioPharma Inc.  At 15753907 - Markets Daily"
p2
aS"Array's Upcoming BRAF-MEK NDA: An Investment Assessment Seeking Alpha - 14 hours ago Array BioPharma  will file another NDA for binimetinib plus encorafenib for BRAF-positive melanoma sometime before June, 2017."
p3
aS"Array BioPharma And Columbus's Egg Seeking Alpha - Mar 15, 2017 Even if we live in the age of immunotherapy and it seems that everything else is old and outdated, a company like Array , which develops small molecule for targeted therapies, has been able to grow up and become a commercial-stage&nbsp;..."
p4
aS"Pre-Market Most Active for Mar 20, 2017 : LYG, ARRY, ESPR, GNMX, HMC, NKTR, DB ... Nasdaq - 17 hours ago Lloyds Banking Group Plc  is -0.01 at $3.48, with 2,017,450 shares traded. LYG's current last sale is 152.63% of the target price of $2.28."
p5
aS'Shares in Focus: Array Biopharma Inc  Davidson Register - 10 hours ago Investors and Traders using technical analysis to study stocks may be looking at the ATR or Average True Range. Presently, Array Biopharma Inc  has a 14-day ATR of 0.62. The Average True Range is an investor tool used to gauge stock volatility.'
p6
aS'Array Biopharma Inc  Expects To File NDA For COLUMBUS / BRAF ... Journal Transcript - Feb 27, 2017 Array Biopharma Inc  a biopharma firm company focused on the development, commercialization and discovery of targeted small molecule cancer treatments, released financial report for its 2Q2017 and offered an update on the&nbsp;...Stock Returns: Array BioPharma Inc  is Beating Natera Inc (NASDAQ ... - CML NewsFMR LLC is the biggest holder of Array BioPharma Inc.  - Post Analyst'
p7
aS"Today's Research Reports on Stocks to Watch: Array Biopharma and Corcept ... Yahoo Finance - Mar 17, 2017 NEW YORK, NY / ACCESSWIRE / March 17, 2017 / Array Biopharma and Corcept Therapeutics are two companies whose stock prices both fell on Thursday, following the trend of the general market."
p8
aS'Biotech Stocks Under Scanner -- MannKind, Opko Health, Celgene, and Array ... PR Newswire  - 19 hours ago Stock-Callers.com today has initiated coverage on MannKind Corp. , Opko Health Inc. , Celgene Corp. , and Array BioPharma Inc. . These companies are engaged in the research and&nbsp;...'
p9
aS"Analyst's Indicator Review for Two Harbors Investment Corp. , Array ... The USA Commerce - Mar 17, 2017 Latest closing price was 5.77% above its 50-day moving average and 12.61% above its 200-day moving average. On 03/16/2017 close, Array BioPharma Inc.  plummeted -1.56% to $10.74. The stock currently has a Market Cap of $1.89B."
p10
a.